Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinphar Pharmaceutical CoTPE:1734 82 EV-to-EBITDA is 10.48 as of Aug. 29, 2026, which is 47% below its 10-year median of 19.83. GuruFocus rates TPE:1734 with a GF Score™ of 82/100 and a GF Value™ of NT$29.90 (Fairly Valued). The stock has 4 warning signs investors should review. Among 414 Biotechnology companies, Sinphar Pharmaceutical Co ranks better than 56.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sinphar Pharmaceutical Co's enterprise value is NT$7,295 Mil.
Sinphar Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$696 Mil. Therefore, Sinphar Pharmaceutical Co's EV-to-EBITDA for today is 10.48.
The historical rank and industry rank for Sinphar Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
TPE:1734'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.59 Med: 19.83 Max: 233.31
Current: 10.48
During the past 13 years, the highest EV-to-EBITDA of Sinphar Pharmaceutical Co was 233.31. The lowest was 9.59. And the median was 19.83.
TPE:1734's EV-to-EBITDA is ranked better than 56.76% of 414
companies
in the Biotechnology industry
Industry Median: 13.55
vs TPE:1734: 10.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sinphar Pharmaceutical Co (TPE:1734) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinphar Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Sinphar Pharmaceutical Co's share price for today is NT$30.75.
Sinphar Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.647.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1734 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's EV-to-EBITDA falls into.
Sinphar Pharmaceutical Co's current Enterprise Value is NT$7,295 Mil.
Sinphar Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$696 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) has a EV-to-EBITDA of 10.48 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sinphar Pharmaceutical Co. This is 47% below median its historical median of 19.83. Over the past decade, Sinphar Pharmaceutical Co's EV-to-EBITDA has ranged from 9.59 to 233.31. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #179 out of 414 companies in the Biotechnology industry, placing it in the top 43.2%.
Is Sinphar Pharmaceutical Co's EV-to-EBITDA too high?
Sinphar Pharmaceutical Co's current EV-to-EBITDA of 10.48 is 47% below median its 10-year median of 19.83. Over the past 10 years, this metric has ranged from a low of 9.59 to a high of 233.31. The Biotechnology industry median EV-to-EBITDA is 13.55. Sinphar Pharmaceutical Co's value of 10.48 is 22.7% below this industry median. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #179 out of 414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #179 out of 414 companies for EV-to-EBITDA. This puts Sinphar Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBITDA is 13.55. Sinphar Pharmaceutical Co's value of 10.48 is 22.7% below this benchmark. Historically, Sinphar Pharmaceutical Co's own EV-to-EBITDA has ranged from 9.59 to 233.31 over the past decade. While the company's 10-year median is 19.83 vs. the industry median of 13.55, Sinphar Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.55, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinphar Pharmaceutical Co's current EV-to-EBITDA of 10.48 is 22.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sinphar Pharmaceutical Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinphar Pharmaceutical Co's current EV-to-EBITDA is 10.48, which is 47% below median its own 10-year median of 19.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.90, compared to a current price of NT$30.75 — trading 2.8% above its estimated fair value. The current EV-to-EBITDA is 10.48, which is 47% below median its 10-year median of 19.83 and 22.7% below the Biotechnology industry median of 13.55. Sinphar Pharmaceutical Co's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current EV-to-EBITDA is 10.48 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be overvalued.
The current stock price of NT$30.75 is trading 2.8% above its estimated GF Value™ of NT$29.90.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
EV-to-EBITDA: 10.48 (47% below median its 10-year median of 19.83)
GF Value™: NT$29.90 vs. price of NT$30.75 (2.8% above fair value)
Industry Position: 22.7% below the Biotechnology median (#179 of 414)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
82GF Score
Get the complete analysis for TPE:1734
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
